Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Auto-Immune Drug Focus - Track Autoimmune Developments Worldwide


News provided by

Research and Markets

24 Sep, 2015, 13:10 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Sept. 24, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/5xz4lp/autoimmune_drug) has announced the addition of the "AutoImmune Drug Focus Issue" newsletter to their offering.

Continue Reading
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

This first approved generic glatiramer acetate has been a long time coming, but the hesitancy in launching shows that the battle to produce a generic Copaxone is not yet over. FDA approval will nonetheless give Sandoz (Novartis) and Momenta Pharmaceuticals grounds to urge the courts to expedite their decision over Copaxone's patents; a launch can be expected immediately upon settlement of this consideration.

A business publication for tracking autoimmune developments worldwide

Do you want to keep up to date with all the latest developments in this important and high-value pharmaceutical area? Autoimmune Drug Focus (ADF) provides a simple, time-saving way to do just that. It summarises all the latest developments in an easy-to-read format, providing company and compound indexes. Can you afford to be without it?

With approximately 4% of the population suffering from an autoimmune disease and with the prevalence of these disorders rising, it is unsurprising that each year, millions of dollars are devoted to researching the causes of autoimmune disorders.

Regular sections in ADF include:

- Type 1 Diabetes
- Inflammatory Bowel Diseases (with features on Crohn's disease and ulcerative colitis)
- Multiple Sclerosis
- Musculoskeletal Disorders (with features on rheumatoid arthritis, and more)
- Psoriasis
- General Developments

Key Topics Covered:

1. First Generic Copaxone Approved But Launch Remains Uncertain Diabetes

2. Agreements

3. AstraZeneca/HSCI Enter Research Collaboration For Diabetes

4. RGI Enters Type I Diabetes Collaboration With JDRF And Pfizer

5.Product Updates
- FDA Accepts Tresiba/Ryzodeg Resubmissions For Review
- Semma Raises Funds To Develop Type I Diabetes Cell Therapy; Signs Deal With Novartis
- Novo Nordisk To Resubmit Tresiba/Ryzodeg NDAs To FDA
- Biocon Gains Mexico Insulin Glargine Approval
- Afrezza Aggressive Pricing Strategy View Playing Out

6. Novo Nordisk Opens Insulin Manufacturing Facility In Russia
- R&D
- Faster-Acting Insulin Aspart Achieves HbA1c Reduction Over NovoRapid In Phase IIIa Trials

7. Oramed Enrols First Patient In Glucose Clamp Study For Oral Insulin Inflammatory Bowel Diseases

8. Agreements
- Low-Risk Investment For Celgene To Translate Into Positive Gains For Small Stem Cell Biotech
- Product Updates
- Qu Biologics Granted US Patent Covering E. Coli Components To Treat CD
- Certain Shire Lialda And Gattex Patents Challenged By Hayman

9. TiGenix Granted US Patent Covering Adipose-Derived Stem Cells For Fistula
- Calprotectin IBDoc Home Test Kit Launched In Europe
- R&D
- Successful Development Of SGX203 Will Corner The Paediatric CD Market

10. Multiple Sclerosis

11. Product Updates
- EMA Validates Zinbryta MAA For MS
- US PTO Declares Interference Between Forward Pharma And Biogen
- Forward Pharma Receives Decision To Grant From EPO For DMF Patent In Europe

12. FDA Accepts Filing Of Betaconnect For RRMS Patients Taking Betaseron
- R&D
- First Patient Enrolled In Laquinimod Phase II Study For PPMS
- Receptos Completes Enrolment In RADIANCE Phase III Trial Of Ozanimod In RMS Musculoskeletal Disorders

13. Arthritis - Agreements
- Coherus And Baxter Amend Etanercept Biosimilar Collaboration
- Product Updates
- EMA Validates Biogen's Infliximab For Review
- Hospira's Infliximab Launched In Canada
- R&D
- Ablynx Initiates Second Phase IIb Of ALX-0061 In RA Psoriasis

14. Agreements
- Janssen Initiates Guselkumab PsA Trial, Triggering Milestone To MorphoSys
- Product Updates
- Humira Gains EU Approval For Plaque Psoriasis In Children
- Dr Reddy's/Promius File Three NDAs With FDA
- R&D
- Can-Fite's CF-101 Phase II/III Psoriasis Trial Misses Primary Endpoint

15. Ixekizumab Trials Are Progressing Well But A Competitive Market Looms - General Developments

16. Agreements
- Intarcia/Numab Collaborate To Develop Therapies In Multiple Indications
- BMS Licenses Autoimmune Research Programme From Novo Nordisk
- Product Updates
- CFDA Accepts IND For WuXi MedImmune's Anti-IL-6 Monoclonal Antibody

17. R&D
- EMA Lupus Guideline Will Encourage New Treatments

18. Behçet's Disease Approval For Otezla Would Boost Celgene's Developing Autoimmune Presence - Corporate Activity

19. Diamyd Medical Receives SEK15mn In Direct Issue
- Valeant Completes Salix Acquisition

20. Novo Nordisk Extends Paediatric Diabetes Programme In Developing Countries
- H216 Will Be Key For High Risk/High Reward Opexa

21. Antares Settles Lawsuits With Medac
- Biogen Will Continue To Gain Share Of MS Market

22. Esbriet Sales Will Reach Blockbuster Status In 2016
- Conference Listings

For more information visit http://www.researchandmarkets.com/research/5xz4lp/autoimmune_drug

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.